Skip to main content
SpringerLink
Log in

Adjuvant Endocrine Therapy

  • Chapter
  • First Online:
Optimizing Breast Cancer Management

Part of the book series: Cancer Treatment and Research ((CTAR,volume 173))

Abstract

The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects. Molecular profiling has allowed therapy to be tailored for an individual patient to some extent. However, further molecular studies are needed to individualize the choice and length of adjuvant hormone therapy. Ongoing studies are evaluating the role of additional targeted therapies, such as CDK4/6 inhibitors, to further improve outcome for patients with early-stage hormone receptor-positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Albain KS et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology 11(1):55–65

    Google Scholar 

  2. Anonymous (2010) Pathologists’ guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Breast Care (Basel) 5(3):185–187

    Google Scholar 

  3. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B et al (2006) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757. Erratum in: N Engl J Med 2006 May 18, 354(20):2200

    Google Scholar 

  4. Buus R et al (2016) Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108(11)

    Google Scholar 

  5. Cardoso F et al (2016) MINDACT investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729

    Article  CAS  PubMed  Google Scholar 

  6. Chia SK et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18(16):4465–4472. Epub 2012 June 18

    Google Scholar 

  7. Coombes R et al (2004) Intergroup exemestane study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092

    Article  CAS  PubMed  Google Scholar 

  8. Davies C et al (2013) Adjuvant tamoxifen: longer against shorter (ATLAS) collaborative group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Eggeman H et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137(2):465–470. Epub 2012 Dec 9

    Google Scholar 

  10. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Google Scholar 

  11. Fisher B et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542

    Article  CAS  PubMed  Google Scholar 

  12. Giordano S et al (2005) Adjuvant systemic therapy for male breast carcinoma. Cancer 104(11):2359

    Article  PubMed  Google Scholar 

  13. Goss P et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802

    Article  CAS  PubMed  Google Scholar 

  14. Goss PE et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013 Apr 10;31(11):1398–1404

    Google Scholar 

  15. Goss P et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209–219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gray R et al, aTTom Collaborative Group (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31(18_suppl):5–5

    Google Scholar 

  17. Howell A et al, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62

    Google Scholar 

  18. Kaufmann M et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25(19):2664–2670. Epub 2007 June 11

    Google Scholar 

  19. Mamounas E et al (2006) NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 7(5):416–421

    Article  CAS  PubMed  Google Scholar 

  20. Mamounas E et al (2016) A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): results from NRG Oncology/NSABP B-42 SABCS 2016, Abstract S1–05

    Google Scholar 

  21. Mamounas E et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677–1683

    Google Scholar 

  22. Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118

    Article  PubMed  PubMed Central  Google Scholar 

  23. Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826

    Article  CAS  PubMed  Google Scholar 

  24. Paik S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734

    Article  CAS  PubMed  Google Scholar 

  25. Province et al (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95(2):216–227

    Article  CAS  PubMed  Google Scholar 

  26. Ribeiro G et al (1992) Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65(2):252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sgroi D et al (2016) Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Res 18:1

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sorlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sparano J et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Wisconsin Carbone Cancer Center, Madison, USA

    Rena Shah & Ruth M. O’Regan

Authors
  1. Rena Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruth M. O’Regan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruth M. O’Regan .

Editor information

Editors and Affiliations

  1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    William J. Gradishar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shah, R., O’Regan, R.M. (2018). Adjuvant Endocrine Therapy. In: Gradishar, W. (eds) Optimizing Breast Cancer Management. Cancer Treatment and Research, vol 173. Springer, Cham. https://doi.org/10.1007/978-3-319-70197-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-70197-4_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-70195-0

  • Online ISBN: 978-3-319-70197-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation